03 September 2018

Director/PDMR Dealing

The Company today announces that on 3 September 2018 Tom Hyland, Chief Operating Officer, purchased 115,988 Ordinary Shares at a purchase price of 4.31p.

Following these purchases, Tom Hyland holds 273,847 Ordinary Shares representing approximately 0.08 per cent of the Company's issued share capital.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Tom Hyland
2 Reason for the notification
a) Position/status Chief Operating Officer
b) Initial notification / Amendment Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code
Ordinary shares of 1p each

ISIN: GB00B94T6Y14
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
4.31p per share 115,988
d) Aggregated information
- Aggregated volume
- Price
N/A - single transaction
e) Date of the transaction 3 September 2018
f) Place of the transaction London Stock Exchange, XLON



Collagen Solutions Plc
Jamal Rushdy, CEO
Hilary Spence, CFO
Via Walbrook
Cenkos Securities plc (Nominated Adviser and Broker)
Steve Cox (Corporate Finance)
Stephen Keys
Tel: 0207 397 8900
Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Helen Cresswell Mob: 07841 917 679